AAI Internal Wiki

SY-5007 RET Inhibitor: A Modern FIH Case Study

閱讀時間約 17 分鐘

SY-5007 RET Inhibitor: A Modern FIH Case Study

SY-5007 RET 抑制劑：現代 FIH 案例研究

English

SY-5007 is a next-generation, highly selective RET (REarranged during Transfection) kinase inhibitor developed for the treatment of advanced solid tumors harboring oncogenic RET alterations — including RET fusions and RET point mutations. Its 2024 FIH dose-escalation and dose-expansion study, published in Signal Transduction and Targeted Therapy, represents one of the most instructive examples currently available of how the modern oncology drug development framework — molecularly enriched patient selection, ctDNA integration, multi-endpoint trial design, and careful attention to resistance mechanisms — looks in practice at the phase 1 stage.

RET is an appealing target in oncology for several reasons. It is a driver in a well-defined molecular subset of thyroid cancers (medullary thyroid carcinoma via RET mutations, papillary thyroid carcinoma via RET fusions), non-small cell lung cancer (primarily RET fusions in NSCLC), and a growing number of other solid tumors where RET fusions are found at lower frequencies. Because RET alterations are bona fide oncogenic drivers rather than passengers, tumors defined by their presence behave more uniformly than all-comer advanced solid tumor populations — making the RET-altered cohort something much closer to a biological signal than a heterogeneous histological category. This is the paradigm shift that tumor-agnostic molecular trials represent: the relevant “disease” is the mutation, not the organ.

The SY-5007 trial enrolled 122 patients with RET-altered solid tumors across a multicenter, open-label dose-escalation and dose-expansion design. Safety endpoints included the standard hierarchy: adverse events by type, grade, and timing; dose-limiting toxicities within the observation window; recommended phase 2 dose (RP2D) determination; and treatment-emergent adverse events requiring dose modification. The most clinically significant treatment-related adverse events (TRAEs) at grade 3 or above included hypertension, diarrhea, hypertriglyceridemia, and neutropenia. This toxicity profile is broadly consistent with other selective RET inhibitors (selpercatinib, pralsetinib) and reflects both on-target and off-target effects of the kinase inhibitor class. Notably, none of these dominant toxicities are acute immune events — they are pharmacological consequences of RET inhibition and kinase off-target activity that accumulate over time, making traditional 21-day DLT windows reasonably adequate for capturing first-cycle signals.

The efficacy data from the dose-expansion cohort generated the kind of numbers that attract attention. Among efficacy-evaluable patients, the overall response rate (ORR) was 57.8%, with a median progression-free survival (PFS) of 21.1 months. These figures are striking for a phase 1 study and deserve careful contextual reading. The enrolled population was molecularly pre-selected for RET alterations — the very definition of a biomarker-enriched cohort. The expansion cohort almost certainly concentrated patients with the best performance status, lowest disease burden, and most interpretable target alteration. Phase 1 expansion cohorts, unlike randomized phase 2 or 3 designs, have no control arm and no pre-specified statistical hypothesis about response rate. The numbers are real and they are impressive; they are not, however, generalizable to an unselected cancer population or even to all RET-altered cancers, and they should not be quoted without that contextual framing.

The ctDNA component of the SY-5007 trial is the most pedagogically rich element for clinicians learning about translational endpoints in FIH trials. The investigators demonstrated that ctDNA clearance — the disappearance of detectable tumor-derived DNA from plasma during treatment — correlated with both treatment response and clinical outcome. Patients who achieved ctDNA clearance were more likely to have objective radiographic responses and better PFS. This is the pharmacodynamic reading that FIH trials need: ctDNA tracking not just mutation status but the dynamic biological response to target inhibition, providing an early molecular signal that the drug is suppressing RET-driven oncogenic signaling.

Equally important was the use of ctDNA in resistance characterization. As patients progressed on SY-5007, serial ctDNA sampling was used to identify emerging resistance mechanisms — including on-target RET kinase domain mutations (analogous to the gatekeeper mutations seen with other kinase inhibitors like the T315I BCR-ABL mutation in CML treated with imatinib) and bypass pathway activations. This is exactly the clinical intelligence that a resistance profiling strategy at progression should generate. It answers the question that the next clinical decision depends on: is this tumor escaping through the original target (necessitating a next-generation inhibitor or combination that blocks the mutant RET), or through a parallel pathway (necessitating a different combination approach)? Tissue biopsy at progression can often answer the same question, but ctDNA liquid biopsy at progression adds spatial sampling across the entire tumor burden rather than the single biopsy site, potentially capturing heterogeneous resistance mechanisms that a single lesion biopsy would miss.

From the clinical pharmacology perspective, the PK data confirmed dose-proportional exposure within the escalation range tested, meaning that higher doses predictably produced higher drug concentrations. This is not trivially true for all kinase inhibitors — some show saturable absorption or nonlinear elimination — and confirming dose-PK linearity is important for understanding whether dose modifications will predictably reduce exposure to a pharmacologically meaningful degree when toxicity management requires them. The trial report did not describe a complex MABEL-based starting dose rationale, which is appropriate: SY-5007 is a targeted small-molecule kinase inhibitor without meaningful immunostimulatory activity, making NOAEL/HNSTD-based starting dose selection from nonclinical safety studies the correct framework. The TGN1412 paradigm does not apply here.

The trial illustrates several teaching points for modern FIH design that go beyond SY-5007 specifically. First, enriching a phase 1 expansion cohort by molecular biomarker rather than tumor histology is now expected, not exceptional, for targeted therapies — and it produces more interpretable efficacy signals than all-comer designs. Second, high ORR in a molecularly enriched phase 1 expansion cohort should be reported with explicit qualifications about selection factors, and clinicians reading those reports should mentally apply those qualifications before generalizing the numbers. Third, ctDNA should be integrated into the translational endpoint plan from the trial’s inception, with pre-specified sampling schedules and molecular response definitions, rather than added as a post-hoc correlative. Fourth, resistance profiling at progression via ctDNA is not a separate research exercise — it is a clinical intelligence function that directly informs what second-line options are worth pursuing, and its infrastructure should be part of the clinical trial design from the start.

The SY-5007 story also illustrates the natural history of a successful early-generation inhibitor in a molecular target class: meaningful activity, manageable toxicity, and then resistance. The field’s response to that arc is the development of next-generation inhibitors and combinations designed to address the resistance mechanisms identified in first-generation trials — exactly what happened with BCR-ABL inhibitors, EGFR inhibitors, and ALK inhibitors before RET. Reading a modern FIH publication like the SY-5007 report means reading not just what happened, but what the resistance data predicts will be needed next.

中文

SY-5007 是一種下一代、高度選擇性的 RET（重排轉染期間基因）激酶抑制劑，開發用於治療攜帶致癌性 RET 改變——包括 RET 融合和 RET 點突變——的晚期實體腫瘤。其 2024 年在 Signal Transduction and Targeted Therapy 發表的 FIH 劑量升量和劑量擴增研究，代表了目前最具指導意義的示範之一：現代腫瘤藥物開發框架——分子富集病人選擇、ctDNA 整合、多終點試驗設計、以及對抗藥性機轉的仔細關注——在第一期試驗階段實際上是什麼樣子。

RET 是腫瘤學中一個吸引人的靶點，原因有幾個。它是明確定義的分子亞型甲狀腺癌（透過 RET 突變的髓樣甲狀腺癌、透過 RET 融合的乳突狀甲狀腺癌）、非小細胞肺癌（主要是 NSCLC 中的 RET 融合），以及越來越多其他頻率較低 RET 融合的實體腫瘤的驅動因子。因為 RET 改變是真正的致癌驅動因子而非過客，由其存在定義的腫瘤比所有參與者的晚期實體腫瘤族群表現更均一——使 RET 改變世代更接近生物訊號而非異質性組織學類別。這是腫瘤無關性分子試驗所代表的範式轉移：相關的「疾病」是突變，而非器官。

SY-5007 試驗在多中心、開放標籤的劑量升量和劑量擴增設計中入組了 122 位 RET 改變實體腫瘤病人。安全性終點包括標準層次：按類型、分級和時間的不良事件；觀察窗內的劑量限制毒性；推薦第二期劑量（RP2D）確定；以及需要劑量調整的治療相關不良事件。最具臨床意義的 3 度或以上治療相關不良事件（TRAE）包括高血壓、腹瀉、高三酸甘油酯血症和嗜中性球減少症。這個毒性特性與其他選擇性 RET 抑制劑（selpercatinib、pralsetinib）大致一致，反映了激酶抑制劑類別的靶點效應和脫靶效應。值得注意的是，這些主要毒性沒有一個是急性免疫事件——它們是 RET 抑制和激酶脫靶活性隨時間積累的藥理後果，使傳統 21 天 DLT 窗口對捕捉第一週期訊號相當適用。

劑量擴增世代的療效資料產生了引人注目的數字。在可評估療效的病人中，整體反應率（ORR）為 57.8%，中位無惡化存活期（PFS）為 21.1 個月。這些數字對第一期研究而言令人印象深刻，需要仔細的情境解讀。入組族群對 RET 改變進行了分子預先選擇——這正是生物標記富集世代的定義。擴增世代幾乎可以確定集中了體能狀態最好、疾病負荷最低、靶點改變最易解讀的病人。第一期擴增世代不像隨機第二期或第三期設計，沒有對照組，也沒有預先規定的反應率統計假說。這些數字是真實的且令人印象深刻；然而，它們不可推廣到未選擇的癌症族群甚至所有 RET 改變的癌症，在沒有這個情境框架的情況下不應被引用。

SY-5007 試驗的 ctDNA 組成部分，是對學習 FIH 試驗轉譯終點的臨床醫師而言教學最豐富的元素。研究者展示了 ctDNA 清除——治療期間血漿中可偵測腫瘤源性 DNA 的消失——與治療反應和臨床結果相關。實現 ctDNA 清除的病人更可能有客觀的影像反應和更好的 PFS。這是 FIH 試驗需要的藥效學讀出：ctDNA 不只追蹤突變狀態，還追蹤對靶點抑制的動態生物反應，提供藥物正在抑制 RET 驅動的致癌訊號傳導的早期分子訊號。

同等重要的是 ctDNA 在抗藥性特性描述中的使用。隨著病人在 SY-5007 上進展，連續 ctDNA 取樣被用來識別新興的抗藥性機轉——包括靶點上的 RET 激酶域突變（類似於其他激酶抑制劑中看到的守門人突變，如 CML 中伊馬替尼治療的 T315I BCR-ABL 突變），以及旁路路徑活化。這正是進展時抗藥性分析策略應該產生的臨床情報。它回答了下一個臨床決策所依賴的問題：這個腫瘤是通過原始靶點逃逸（需要次世代抑制劑或阻斷突變型 RET 的組合），還是通過平行路徑（需要不同的組合方法）？進展時的組織切片通常可以回答同樣的問題，但進展時的 ctDNA 液態切片在整個腫瘤負荷中增加了空間取樣，而不只是單個切片部位，有可能捕捉到單個病灶切片會遺漏的異質性抗藥性機轉。

從臨床藥理學角度，PK 資料確認了在測試的升量範圍內與劑量成比例的暴露，意味著較高劑量可預測地產生較高藥物濃度。這對所有激酶抑制劑而言並不是理所當然——有些顯示飽和性吸收或非線性消除——且確認劑量—PK 線性對於理解當毒性管理需要時，劑量調整是否會可預測地將暴露降低到藥理上有意義的程度很重要。試驗報告沒有描述複雜的 MABEL 基礎起始劑量理由，這是適當的：SY-5007 是沒有有意義免疫刺激活性的靶向小分子激酶抑制劑，使從非臨床安全研究的 NOAEL/HNSTD 基礎起始劑量選擇成為正確框架。TGN1412 範式在這裡不適用。

這個試驗說明了幾個超越 SY-5007 本身的現代 FIH 設計教學點。第一，對靶向療法而言，通過分子生物標記而非腫瘤組織學富集第一期擴增世代，現在是預期的，而非例外的——且它比所有參與者設計產生更可解讀的療效訊號。第二，分子富集第一期擴增世代中高 ORR 應附帶選擇因素的明確資格限定報告，而閱讀這些報告的臨床醫師應在推廣數字之前在心理上應用這些限定。第三，ctDNA 應從試驗開始就整合到轉譯終點計劃中，具有預先規定的採血時程和分子反應定義，而非作為事後相關性研究添加。第四，進展時通過 ctDNA 進行的抗藥性分析不是獨立的研究練習——它是直接告知值得追求的二線選項的臨床情報功能，其基礎設施應從一開始就成為臨床試驗設計的一部分。

SY-5007 的故事也說明了分子靶點類別中成功早期抑制劑的自然史：有意義的活性、可管理的毒性，然後是抗藥性。這個領域對這個弧線的回應，是開發旨在解決第一代試驗中識別的抗藥性機轉的次世代抑制劑和組合——這正是 BCR-ABL 抑制劑、EGFR 抑制劑和 ALK 抑制劑在 RET 之前發生的事情。閱讀像 SY-5007 報告這樣的現代 FIH 出版物，意味著不只閱讀發生了什麼，還閱讀抗藥性資料預測接下來需要什麼。

Key Concepts | 核心概念

  • RET (REarranged during Transfection): a receptor tyrosine kinase gene whose fusions and activating mutations are oncogenic drivers in thyroid cancer, NSCLC, and other solid tumors. RET alterations define a tumor-agnostic biomarker-enriched patient population.
  • Tumor-agnostic molecular cohort: a phase 1 expansion cohort defined by molecular alteration across histologies rather than by organ of origin. Produces more biologically homogeneous data but requires robust molecular pre-screening.
  • ctDNA clearance: the disappearance of detectable circulating tumor DNA during treatment, used in SY-5007 as a pharmacodynamic endpoint correlating with response. Distinct from baseline ctDNA measurement.
  • On-target resistance: resistance mutations within the targeted kinase domain (e.g., RET kinase domain mutations) that sterically or allosterically prevent drug binding. Analogous to T315I in CML/imatinib resistance.
  • Bypass resistance: activation of parallel signaling pathways (e.g., MET amplification, KRAS mutation) that restore proliferative signaling despite effective target inhibition. May require combination rather than next-generation inhibitor strategy.
  • Dose-PK linearity: confirmation that drug exposure (AUC, Cmax) increases proportionally with dose — important for predicting that dose modifications will produce predictable exposure changes.
  • ORR in phase 1 expansion (caution framing): overall response rate in a molecularly pre-selected, performance-status-enriched, single-arm expansion cohort reflects selection effects that must be acknowledged when comparing to historical all-comer or randomized trial data.

Related Pages | 相關頁面

關係圖譜

反向連結